Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
作者: Aaron C. TanGillianne G.Y. LaiGek San TanShou Yu PoonBrett DobleTse Hui LimZaw Win AungAngela TakanoWan Ling TanMei-Kim AngBien Soo TanAnantham DevanandChow Wei TooApoorva GognaBoon-Hean OngTina P.T. KohRavindran KanesvaranQuan Sing NgAmit JainTanujaa RajasekaranAlvin S.T. LimWan Teck LimChee Keong TohEng-Huat TanTony Kiat Hon LimDaniel S.W. Tan
作者单位: 1Division of Medical Oncology, National Cancer Centre Singapore, Singapore
2Division of Pathology, Singapore General Hospital, Singapore
3Duke-NUS Medical School, National University of Singapore, Singapore
4Department of Vascular and Interventional Radiology, Singapore General Hospital, Singapore
5Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore
6Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore
刊名: Lung Cancer, 2020, Vol.139 , pp.207-215
来源数据库: Elsevier Journal
DOI: 10.1016/j.lungcan.2019.11.022
关键词: Molecular profilingNext-generation sequencing (NGS)Non-small cell lung cancer (NSCLC)Oncogenic driversTargeted therapy
原始语种摘要: Abstract(#br)Objectives(#br)There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsies is an increasingly encountered problem. We sought to compare the performance of targeted next-generation sequencing (NGS) panels with traditional assays and correlate the mutational landscape with PD-L1 status in Singaporean patients.(#br)Materials and methods(#br)We identified consecutive patients diagnosed between Jan 2016 to Sep 2017 with residual tissue after standard molecular testing. Tissue samples were tested using a targeted NGS panel for DNA alterations (29 selected genes including BRAF , EGFR , ERBB2 and TP53 )...
全文获取路径: Elsevier  (合作)
影响因子:3.392 (2012)

  • population 母体
  • generation 世代
  • cancer 癌症
  • effectiveness 有效性
  • upfront 第一位的
  • sequencing 排序
  • targeted 对准目标的
  • compared 肿瘤和正常组织细胞周期的比较
  • analysis 分析